NASDAQ: LXEO

Lexeo Therapeutics, Inc. Common Stock

Healthcare | Biotechnology

No licensed closing price on file for LXEO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Lexeo Therapeutics, Inc. Common Stock (NASDAQ: LXEO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:59 UTC.

What Lexeo Therapeutics, Inc. Common Stock does

This company is a clinical-stage genetic medicine company focused on developing gene therapies to treat cardiovascular diseases caused by genetic mutations. The company's most advanced candidate, LX2006, targets Friedreich ataxia cardiomyopathy and is being evaluated in ongoing Phase 1/2 trials with positive interim safety and efficacy data reported. The second most advanced candidate, LX2020, targets arrhythmogenic cardiomyopathy caused by PKP2 mutations and is also in Phase 1/2 trials showing positive interim results.

Summarized from Lexeo Therapeutics, Inc. Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-29
Return on equity	52.48%

Charts

Charts are in the appInteractive charts for LXEO are available in Oxford Ledge.
Open LXEO in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-28

2026-09-28Chief Executive OfficerStock Option (right to buy)Award145,500—
2026-09-28Chief Executive OfficerAward2,306$6.1K
2026-09-28Chief Medical OfficerAward2,714$9.7K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

MONTANOVA CAPITAL, LLC6,384,200$29.72M+410.7%
Affinity Asset Advisors, LLC5,807,611$27.03M+15.0%
BlackRock, Inc.5,739,455$26.72M+12.3%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-04-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersLaura Sepp-LorenzinoEstimatedSEC 8-K →
2025-08-14Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersKyle RasbachAuthoritativeSEC 8-K →
2024-12-19Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersKyle RasbachAuthoritativeSEC 8-K →

Company news

View all →

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call - Slideshow
Seeking Alpha Feed2026-06-15
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Lexeo Therapeutics, Inc. Common Stock do?

This company is a clinical-stage genetic medicine company focused on developing gene therapies to treat cardiovascular diseases caused by genetic mutations.

When did LXEO last file with the SEC?

Lexeo Therapeutics, Inc. Common Stock's most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:59 UTC. This page is also available as JSON at /api/data?ticker=LXEO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LXEO and 5,000+ tickers.

Create a free account — keep LXEO

For your agent

GET /api/data?ticker=LXEO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt